The conversation is about the availability of gt20029 for hair loss treatment, indicating that it will not be available for purchase soon. No specific treatments were discussed.
A 26-year-old is experiencing hair thinning and has received conflicting diagnoses of androgenetic alopecia and telogen effluvium. They are considering treatments like dutasteride, oral and topical minoxidil, and are unsure whether to start treatment or pursue further diagnosis like a scalp biopsy.
The user started finasteride and derma rolling for hair loss, later switching to wet cupping therapy. They experienced initial shedding but reported thicker, healthier hair over time, using natural hair wash methods like Amla, Reetha, and Shikakai.
Follicum discovered that their drug FOL-005 increased hair count by 12 hairs per cm2 in patients with less than 255 hairs per cm2 and is planning a phase 2b trial. They are currently fundraising for the trial, and the drug may also be effective for women.
RU58841 is not recommended for use around children due to potential exposure risks. Alternatives like CB-03-01 might be considered, but further research is advised.
The conversation discusses concerns about a new rule affecting orders of hair loss treatments like Minoxidil, finasteride, and RU58841. Users are worried about the impact on their ability to obtain these products.
A 29-year-old male with diffuse thinning plans to start minoxidil and finasteride soon but is concerned about potential shedding before a big event in late April/early May. He is considering whether to start treatment now or wait until after the event.
The user is considering switching from finasteride to RU-58841 for hair loss due to side effects and is concerned about its safety around cats. They are also seeking dosage suggestions and alternatives like pyrilutamide.